WALTHAM, Mass.–(BUSINESS WIRE)–Avedro, Inc., a privately held medical device and pharmaceutical company, today announced C. Evan Ballantyne as Chief Financial Officer. In this position, Mr. Ballantyne will be responsible for the Company’s financial affairs and report to David Muller, PhD, President and Chief Executive Officer. Prior to this role, Mr. Ballantyne served as Executive Vice President, Chief Financial Officer of Clinical Data, Inc., a biopharmaceutical company which was acquired in April 2011 by Forest Laboratories, Inc. for $1.3 billion.
“I am looking forward to working closely with Evan as Avedro continues to expand its cross-linking technologies for use in the strengthening of corneas weakened by disease and in performing Lasik Xtra, an adjunct to all Lasik procedures,” commented David Muller. “Evan brings relevant operating experience in public and private company environments, and significant financial and strategic experience within the health care and biotechnology industries.”
Prior to his roles at Avedro and Clinical Data, Ballantyne was Chief Financial Officer of ZymeQuest, Inc., a medical technology company based in Beverly, Massachusetts. He also served as the Chief Financial Officer of Knowledge Impact. Ballantyne was Vice President and Chief Operating Officer for ACNielsen Corporation and held the Chief Financial Officer position as well for 2 years. There, he was responsible for all aspects of operations, strategic planning and finance in more than 45 countries for a corporation with 9,700 employees. At ACNielsen, he drove productivity gains and cost savings activities while holding expenses flat with the prior year and helped develop new revenue opportunities while implementing a cross-border sales tracking system. He also helped lead the company’s successful ISO certification in three countries. Ballantyne also held an audit position for Dun & Bradstreet, earned a B.A. from the University of Western Ontario, and took a post-graduate degree in Business Administration with Honors from the University of Windsor.
About Avedro, Inc.
Avedro is a privately held medical device and pharmaceutical company based in Waltham, MA, and developed VibeX™ Riboflavin and the KXL™ System for performing Accelerated Cross-linking. Avedro recently completed multi-centered US‐based Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and post LASIK ectasia. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. Keraflex® is the first technology Avedro has developed from its Thermo‐biomechanics platform. The Keraflex procedure is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue, offering the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with LASIK and other refractive correction procedures. Keraflex and KXL are CE Marked and commercially available outside of the United States.
Kristen Gleason, 781-768-3400